Covered recipient · General Payments record
IFTIKHAR HUSSAIN
Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$12,718.83
171 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $5,098.99 | 158 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,600.00 | 1 |
| Consulting Fee | $2,292.00 | 1 |
| Travel and Lodging | $1,693.84 | 10 |
| Education | $34.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $3,755.32 | 6 |
| GENZYME CORPORATION | $3,239.36 | 28 |
| Novartis Pharmaceuticals Corporation | $1,412.22 | 16 |
| AstraZeneca Pharmaceuticals LP | $1,288.17 | 32 |
| Insmed, Inc. | $1,268.94 | 12 |
| CSL Behring | $241.33 | 13 |
| PFIZER INC. | $240.93 | 12 |
| GlaxoSmithKline, LLC. | $202.64 | 14 |
| Grifols USA, LLC | $188.37 | 8 |
| Blueprint Medicines Corporation | $185.45 | 4 |
| Galderma Laboratories, L.P. | $180.55 | 5 |
| Amgen Inc. | $179.53 | 5 |
| Regeneron Healthcare Solutions, Inc. | $155.02 | 7 |
| ARS Pharmaceuticals Operations, Inc. | $67.69 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $52.00 | 3 |
| Organon LLC | $30.33 | 1 |
| Optinose US, Inc. | $16.96 | 1 |
| Genentech USA, Inc. | $14.02 | 1 |
Page 3 of 4; records 101–150 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
IFTIKHAR HUSSAIN
NPI 1205854015 · CMS profile ID 191178
Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology
TULSA, OK
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1205854015?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- IFTIKHAR HUSSAIN, NPI 1205854015, CMS profile ID 191178. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205854015?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). IFTIKHAR HUSSAIN, NPI 1205854015, CMS profile ID 191178. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205854015?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- IFTIKHAR HUSSAIN, NPI 1205854015, CMS profile ID 191178, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1205854015?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
171 matching records · $12,718.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 171.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Insmed, Inc. | $23.82 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186254521 | CMS |
| Insmed, Inc. | $12.83 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186254523 | CMS |
| Insmed, Inc. | $24.88 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186269456 | CMS |
| Insmed, Inc. | $70.87 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186269458 | CMS |
| Insmed, Inc. | $24.88 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186269460 | CMS |
| Insmed, Inc. | $52.14 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186269462 | CMS |
| Insmed, Inc. | $123.49 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186269466 | CMS |
| Insmed, Inc. | $12.60 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186310009 | CMS |
| Insmed, Inc. | $48.40 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186310011 | CMS |
| Insmed, Inc. | $12.60 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186310013 | CMS |
| Insmed, Inc. | $157.49 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186310015 | CMS |
| Insmed, Inc. | $704.94 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186310017 | CMS |
| Optinose US, Inc. | $16.96 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1163258478 | CMS |
| Galderma Laboratories, L.P. | $14.56 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234657238 | CMS |
| GlaxoSmithKline, LLC. | $7.96 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190733998 | CMS |
| PFIZER INC. | $5.48 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229021824 | CMS |
| GENZYME CORPORATION | $28.24 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325127 | CMS |
| GENZYME CORPORATION | $28.56 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325129 | CMS |
| CSL Behring | $2.83 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232352258 | CMS |
| CSL Behring | $2.83 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232352260 | CMS |
| Blueprint Medicines Corporation | $27.53 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235820185 | CMS |
| PFIZER INC. | $14.82 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228927842 | CMS |
| CSL Behring | $21.49 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232352256 | CMS |
| GENZYME CORPORATION | $16.47 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325119 | CMS |
| CSL Behring | $13.96 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232352252 | CMS |
| GlaxoSmithKline, LLC. | $7.32 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191102094 | CMS |
| PFIZER INC. | $4.21 | 04/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228941574 | CMS |
| GENZYME CORPORATION | $118.98 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325115 | CMS |
| GlaxoSmithKline, LLC. | $14.55 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190694288 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.07 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207014455 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.56 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207271233 | CMS |
| GENZYME CORPORATION | $25.81 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325109 | CMS |
| PFIZER INC. | $2.91 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228936435 | CMS |
| GlaxoSmithKline, LLC. | $16.82 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190928646 | CMS |
| Blueprint Medicines Corporation | $121.82 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235820413 | CMS |
| GENZYME CORPORATION | $24.67 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325117 | CMS |
| Blueprint Medicines Corporation | $19.43 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235820160 | CMS |
| ARS Pharmaceuticals Operations, Inc. | $23.68 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245878460 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.52 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206798225 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.00 | 03/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206277697 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.34 | 03/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223860254 | CMS |
| GENZYME CORPORATION | $30.76 | 03/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325105 | CMS |
| GENZYME CORPORATION | $17.40 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325103 | CMS |
| AstraZeneca Pharmaceuticals LP | $122.41 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207181892 | CMS |
| Galderma Laboratories, L.P. | $10.43 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234657236 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.12 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206156738 | CMS |
| GlaxoSmithKline, LLC. | $15.71 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190693488 | CMS |
| Amgen Inc. | $131.49 | 03/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228495060 | CMS |
| GENZYME CORPORATION | $92.50 | 03/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325085 | CMS |
| GENZYME CORPORATION | $27.23 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233325099 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $629,788.33 | 134 |
| PY2024 | Recipient | $2,905.87 | 20 |
| PY2024 | Principal investigator | $628,299.41 | 288 |
| PY2023 | Recipient | $4,519.45 | 21 |
| PY2023 | Principal investigator | $635,851.56 | 145 |
| PY2022 | Recipient | $1,420.86 | 3 |
| PY2022 | Principal investigator | $809,681.00 | 155 |
| PY2021 | Recipient | $4,914.51 | 13 |
| PY2021 | Principal investigator | $1,135,913.89 | 172 |
| PY2020 | Recipient | $35,787.20 | 37 |
| PY2020 | Principal investigator | $1,489,586.31 | 235 |
| PY2019 | Recipient | $8,763.38 | 14 |
| PY2019 | Principal investigator | $1,610,045.70 | 236 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
134 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25,650.00 | 12/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192132293 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,397.60 | 12/19/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192132286 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,091.60 | 12/19/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223289944 |
| Principal investigator 1 | PFIZER INC. | $5,553.91 | 12/17/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228816142 |
| Principal investigator 1 | PFIZER INC. | $2,712.83 | 12/16/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228817027 |
| Principal investigator 1 | PFIZER INC. | $4,732.09 | 12/11/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228817065 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,440.80 | 12/08/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086522 |
| Principal investigator 1 | ABBVIE INC. | $4,418.00 | 12/04/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202527060 |
| Principal investigator 1 | PFIZER INC. | $5,552.37 | 11/26/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228818303 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,547.00 | 11/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183414 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,137.10 | 11/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183457 |
| Principal investigator 1 | PFIZER INC. | $3,476.70 | 11/18/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228818309 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $1,648.65 | 11/17/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555035 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,809.60 | 11/10/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086607 |
| Principal investigator 1 | PFIZER INC. | $4,877.62 | 10/31/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228826124 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $954.90 | 10/23/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223287373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.00 | 10/20/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184251518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.00 | 10/20/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184251520 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,381.00 | 10/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183422 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $853.20 | 10/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183445 |
| Principal investigator 1 | ABBVIE INC. | $1,809.70 | 10/09/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202514203 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,801.80 | 10/06/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086603 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,244.41 | 10/02/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192182046 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $81,836.35 | 10/02/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183431 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $5,090.91 | 10/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555033 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $140.00 | 10/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190304303 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 10/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223286013 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,280.00 | 09/24/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185550747 |
| Principal investigator 1 | PFIZER INC. | $2,274.36 | 09/24/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228835495 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,809.90 | 09/23/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223285810 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,200.00 | 09/19/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185550749 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $954.90 | 09/18/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223285630 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,659.00 | 09/15/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226086599 |
| Principal investigator 1 | PFIZER INC. | $2,226.08 | 09/10/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228835490 |
| Principal investigator 1 | PFIZER INC. | $2,112.08 | 09/09/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228835538 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,184.00 | 09/08/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183435 |
| Principal investigator 1 | Optinose US, Inc. | $6,500.00 | 09/05/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute, P.C. | A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1163251991 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,299.50 | 09/04/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223285097 |
| Principal investigator 1 | ABBVIE INC. | $354.40 | 09/03/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507777 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,228.40 | 09/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192182042 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,792.40 | 09/03/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086595 |
| Principal investigator 1 | ABBVIE INC. | $4,055.86 | 08/25/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202505699 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,310.87 | 08/25/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,994.40 | 08/18/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086589 |
| Principal investigator 1 | ABBVIE INC. | $1,978.50 | 08/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202504807 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 08/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223284243 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,930.00 | 08/13/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183409 |
| Principal investigator 1 | PFIZER INC. | $4,783.66 | 08/09/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228843507 |
| Principal investigator 1 | ABBVIE INC. | $408.90 | 08/05/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501826 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,845.60 | 08/04/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183426 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $175.00 | 08/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223283309 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,310.87 | 07/28/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554935 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,310.00 | 07/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183405 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,971.54 | 07/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183441 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 07/22/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223282894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.00 | 07/18/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217497 |
| Principal investigator 1 | PFIZER INC. | $2,041.20 | 07/16/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228848219 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,975.85 | 07/14/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086585 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 07/04/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223282224 |
| Principal investigator 1 | ABBVIE INC. | $302.60 | 07/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202495611 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 07/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281928 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 07/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281932 |
| Principal investigator 1 | PFIZER INC. | $21,289.29 | 06/26/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228851929 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 06/26/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228851936 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,675.00 | 06/20/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183401 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,212.10 | 06/20/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183449 |
| Principal investigator 1 | Eli Lilly and Company | $3,000.00 | 06/16/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INST PC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187893458 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,780.04 | 06/16/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555001 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,442.00 | 06/16/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226086576 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 06/12/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281130 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,446.54 | 06/09/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086581 |
| Principal investigator 1 | Eli Lilly and Company | $5,870.10 | 06/05/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INST PC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187893456 |
| Principal investigator 1 | ABBVIE INC. | $971.30 | 06/03/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202489287 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,156.48 | 06/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190304305 |
| Principal investigator 1 | PFIZER INC. | $2,695.00 | 05/30/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228857728 |
| Principal investigator 1 | PFIZER INC. | $25,460.40 | 05/29/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228855701 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,376.95 | 05/27/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226086567 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,587.00 | 05/27/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | CSU - Patient study in children aged 2 years to < 12 years | No dispute reported | 06/30/2026 | 1226086571 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 05/22/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223280140 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,527.10 | 05/21/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183396 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $4,731.72 | 05/19/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555003 |
| Principal investigator 1 | ABBVIE INC. | $1,770.70 | 05/06/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202481527 |
| Principal investigator 1 | ABBVIE INC. | $97.50 | 05/06/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202481531 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,868.43 | 05/05/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086563 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $175.00 | 05/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223278726 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 04/28/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223278648 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,036.20 | 04/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183418 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 04/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615703 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 04/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615707 |
| Principal investigator 1 | Incyte Corporation | $36.00 | 04/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615710 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 04/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615714 |
| Principal investigator 1 | Incyte Corporation | $2,000.70 | 04/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615721 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 04/14/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615730 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,408.54 | 04/08/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190304301 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,222.10 | 04/08/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223277624 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,066.75 | 04/07/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086555 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 04/04/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | No dispute reported | 06/30/2026 | 1192182038 |
| Principal investigator 1 | ABBVIE INC. | $299.00 | 04/03/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202469217 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 04/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615718 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 04/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615727 |
| Principal investigator 1 | Incyte Corporation | $11.52 | 04/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615732 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 04/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615735 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,299.50 | 03/19/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223276783 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,474.90 | 03/17/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086543 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,310.87 | 03/10/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554971 |
| Principal investigator 1 | ABBVIE INC. | $1,570.90 | 03/06/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202457867 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,820.00 | 03/04/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086539 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,608.00 | 02/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 02/25/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223275513 |
| Principal investigator 1 | Incyte Corporation | $2,117.70 | 02/19/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615687 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,577.58 | 02/18/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086535 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,897.04 | 02/10/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554969 |
| Principal investigator 1 | ABBVIE INC. | $4,546.00 | 02/05/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202445041 |
| Principal investigator 1 | ABBVIE INC. | $2,076.90 | 02/05/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202445043 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 02/05/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223274765 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,766.10 | 01/27/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086530 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,768.50 | 01/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192183462 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $580.00 | 01/21/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086547 |
| Principal investigator 1 | Incyte Corporation | $1,453.80 | 01/17/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615684 |
| Principal investigator 1 | Incyte Corporation | $1,671.00 | 01/17/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615689 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 01/17/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223274013 |
| Principal investigator 1 | ABBVIE INC. | $1,617.40 | 01/15/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202438709 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $135.48 | 01/15/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190304299 |
| Principal investigator 1 | PFIZER INC. | $400.00 | 01/15/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research Institute PC | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228863639 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $4,621.74 | 01/13/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554973 |
| Principal investigator 1 | Eli Lilly and Company | $15,939.90 | 01/07/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INST PC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187893690 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $1,227.98 | 01/07/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554963 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $500.00 | 01/07/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554965 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $1,606.56 | 01/07/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554967 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,088.90 | 01/07/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223273641 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,580.00 | 01/06/2025 | Non-covered Recipient Entity Vital Prospects Clinical Research I Institute PC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226086558 |
| Principal investigator 1 | Incyte Corporation | $123.90 | 01/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615693 |
| Principal investigator 1 | Incyte Corporation | $66.24 | 01/02/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240615698 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,087.83 | 01/01/2025 | Non-covered Recipient Entity VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190304307 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2021 | Amount invested | $70,000.00 | 1 |
| PY2021 | Value of interest | $70,000.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
1 record · PY2021
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2021 | Medico CX Inc | $70,000.00 | $70,000.00 | 167,865 shares at $0.42 each | Physician Covered Recipient | No dispute reported | 06/30/2026 | 855029437 |